On November 17, 2020 Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced the release of 10 abstracts that will be presented at the 2020 Virtual San Antonio Breast Cancer Symposium (SABCS) from Dec 8-11, 2020 (Press release, Puma Biotechnology, NOV 17, 2020, View Source [SID1234571287]). Abstracts are available to the public online on the SABCS website at www.sabcs.org.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Spotlight poster discussions are as follows:

PD1-05

Title: Latest findings from the breast cancer cohort in SUMMIT – a phase 2 ‘basket’ trial of neratinib + trastuzumab + fulvestrant for HER2-mutant, hormone receptor-positive, metastatic breast cancer

Presenter: Komal Jhaveri, M.D., Ph.D

Wednesday, Dec. 9, 4:00 – 5:15 p.m. CT

PD3-03

Title: Continued efficacy of neratinib in patients with HER2-positive early-stage breast cancer: Final overall survival analysis from the randomized phase 3 ExteNET trial

Presenter: Frankie Ann Holmes, M.D., FACP

Wednesday, Dec. 9, 6:30 – 7:45 p.m. CT

PD13-09

Title: Impact of neratinib on outcomes in HER2-positive metastatic breast cancer patients with central nervous system disease at baseline: Findings from the phase 3 NALA trial

Presenter: Cristina Saura, M.D., Ph.D.

Friday, Dec. 11, 1:00 – 2:15 p.m. CT

Additional posters to be presented on Wednesday, Dec. 9, beginning at 8:00 a.m. CT are as follows:

PS13-20

Title: Bringing diarrhea under CONTROL: dose escalation reduces neratinib-associated diarrhea and improves tolerability in HER2-positive early-stage breast cancer

Presenter: Manuel Ruiz-Borrego, M.D.

PS9-02

Title: Neratinib + capecitabine sustains health-related quality of life (HRQoL) while improving progression-free survival (PFS) in patients with HER2+ metastatic breast cancer and ≥2 prior HER2-directed regimens

Presenter: Beverly Moy, M.D., M.P.H.

PS7-61

Title: The Neat-HER Virtual Registry: Results on HER2+ breast cancer patients receiving neratinib as extended adjuvant therapy

Presenter: Hope Rugo, M.D.

PS10-45

Title: Budget impact of introducing neratinib for third-line treatment of HER2+ metastatic breast cancer in the United States

Presenter: Seri Anderson, Ph.D.

PS9-33

Title: Cost-effectiveness of neratinib for the extended adjuvant treatment of adult patients with early-stage, HR+, HER2-overexpressed/amplified breast cancer who initiated neratinib within 1 year of completing trastuzumab in the US

Presenter: Adam Brufsky, M.D,, Ph.D.

PS9-54

Title: Healthcare costs for metastatic breast cancer patients treated with human epidermal growth factor receptor 2 targeted agents

Presenter: Reshma Mahtani, D.O.

PS10-22

Title: Breast cancer mortality in women with HER2+ disease treated in a large integrated healthcare system

Presenter: Reina Haque, Ph.D., M.P.H.